Phase IIb data show SVR12 in Hepatitis C patients treated with BI 201335 (Boehringer Ingelheim)

A sub-analysis from SOUND-C2, a Phase IIb study in patients with Hepatitis C evaluating interferon-free treatment with investigational antiviral compounds BI 201335 and BI 207127, from Boehringer Ingelheim, plus ribavirin (RBV), show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b Hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure. This is the first dataset for an interferon-free regimen in HCV patients with compensated liver cirrhosis. The study includes 362 treatment-naive GT1 HCV patients, randomized into five interferon-free treatment groups, each with 120 mg BI 201335 once-daily but with different dosing of BI 207127 and treatment durations. Data was presented at the International Liver Congress by Stefan Zeuzem, M.D., Chief of the Department of Medicine and Professor of Medicine at the Johann Wolfgang Goethe University Hospital in Frankfurt, Germany.